Insmed Inc (INSM)

$145.93 +0.14 (0.10%)
Market Cap 30.85B
Revenue (ttm) 363.71M
Net Income (ttm) -913.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -251.24%
Debt to Equity Ratio 0.43
Volume 1,926,400
Avg Vol 2,639,562
Day's Range N/A - N/A
Shares Out 211.38M
Stochastic %K 65%
Beta 0.97
Analysts Strong Sell
Price Target $156.24

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 977 9900
Address:
700 US Highway 202/206, Bridgewater, United States
bemore
bemore Sep. 13 at 2:10 PM
$INSM In its second-quarter 2025 investor letter, TimesSquare Capital Small Cap Growth Strategy highlighted stocks such as Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company that develops therapeutic products for patients with serious and rare diseases. The one-month return of Insmed Incorporated (NASDAQ:INSM) was 14.12%, and its shares gained 97.25% of their value over the last 52 weeks. "Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that deserve premium pricing, or specialized service providers. Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company engaged in developing therapies for patients with rare diseases, jumped 31%. During the quarter, the company reported impressive safety and efficacy data from its Phase 2 trial of Treprostinil Palmitil inhalation powder for treating arterial hypertension."
0 · Reply
kelrock90
kelrock90 Sep. 11 at 4:59 PM
$INSM premarket for 9-11-25 was $175.62
2 · Reply
pianoman439
pianoman439 Sep. 11 at 1:00 PM
$INSM how can you not love the action of Insmed stock? How can you not grieve the tragedy and recent tragedies in my nation? 😢
0 · Reply
Hello_AI
Hello_AI Sep. 11 at 6:21 AM
$INSM bullish
0 · Reply
pianoman439
pianoman439 Sep. 10 at 3:17 PM
$INSM
0 · Reply
pianoman439
pianoman439 Sep. 10 at 12:10 PM
$INSM JP Morgan Buy 153
0 · Reply
TalkMarkets
TalkMarkets Sep. 10 at 9:34 AM
Potential Pause In Gold Futures Rally? Here's What Wyckoff Effort Vs. Results Reveals $RDDT $INSM $WWW $GLD $SLV https://talkmarkets.com/content/commodities/potential-pause-in-gold-futures-rally-heres-what-wyckoff-effort-vs-results-reveals?post=521612&userid=166882
0 · Reply
pianoman439
pianoman439 Sep. 10 at 1:19 AM
$INSM what an awesome presentation! What a miraculous story! And that’s only the half of it. ALS and DMD research is bringing Insmed full circle from the days Genentech tried to destroy the tiny fledgling Insmed over a paradigm changing short stature compound.
1 · Reply
JoeB07
JoeB07 Sep. 9 at 9:21 PM
$INSM CEO describes company as a "freight train". Going to be an epic year.
0 · Reply
AlbertSan
AlbertSan Sep. 9 at 9:20 PM
$INSM
0 · Reply
Latest News on INSM
Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 12:10 PM EDT - 3 days ago

Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 10:49 AM EDT - 8 days ago

Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sep 5, 2025, 7:00 AM EDT - 8 days ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed To Present at September Investor Conferences

Aug 21, 2025, 7:00 AM EDT - 23 days ago

Insmed To Present at September Investor Conferences

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

Aug 20, 2025, 2:46 PM EDT - 24 days ago

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

Josh Brown's Best Stocks in the Market: Insmed

Aug 19, 2025, 1:04 PM EDT - 25 days ago

Josh Brown's Best Stocks in the Market: Insmed

Insmed CEO on what's next for company after FDA greenlights lung disease drug

Aug 13, 2025, 6:15 PM EDT - 4 weeks ago

Insmed CEO on what's next for company after FDA greenlights lung disease drug

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

Aug 12, 2025, 2:20 PM EDT - 4 weeks ago

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

US FDA approves Insmed's lung disease drug

Aug 12, 2025, 11:42 AM EDT - 4 weeks ago

US FDA approves Insmed's lung disease drug

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Aug 12, 2025, 11:34 AM EDT - 4 weeks ago

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:20 PM EDT - 5 weeks ago

Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

Aug 7, 2025, 9:35 PM EDT - 5 weeks ago

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

ARGX COO ELV HQY IDXX ISRG RDNT

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:00 AM EDT - 5 weeks ago

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

Jul 30, 2025, 12:37 PM EDT - 6 weeks ago

Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains.

AMGN BBIO

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

Jul 24, 2025, 7:00 AM EDT - 7 weeks ago

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 2 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BBIO BMRN GILD XBI

Is Insmed Stock Overvalued After The 45% Jump?

Jun 16, 2025, 5:05 AM EDT - 3 months ago

Is Insmed Stock Overvalued After The 45% Jump?

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Jun 11, 2025, 10:25 PM EDT - 3 months ago

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Jun 11, 2025, 4:01 PM EDT - 3 months ago

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Jun 11, 2025, 1:32 PM EDT - 3 months ago

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Insmed CEO Will Lewis on stock surge after positive trial results

Jun 10, 2025, 5:56 PM EDT - 3 months ago

Insmed CEO Will Lewis on stock surge after positive trial results

Insmed: Company Presses On With Further POC PAH Treatment Data

Jun 10, 2025, 4:30 PM EDT - 3 months ago

Insmed: Company Presses On With Further POC PAH Treatment Data

Insmed's blood pressure drug meets main goal in mid-stage trial

Jun 10, 2025, 7:25 AM EDT - 3 months ago

Insmed's blood pressure drug meets main goal in mid-stage trial

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

Jun 10, 2025, 7:00 AM EDT - 3 months ago

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

Mizuho's Jared Holz details potential biotech, pharma acquisitions

Jun 4, 2025, 6:10 PM EDT - 3 months ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

LEGN VRNA

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

May 28, 2025, 7:10 AM EDT - 3 months ago

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

May 21, 2025, 4:05 PM EDT - 4 months ago

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:55 PM EDT - 4 months ago

Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:00 AM EDT - 4 months ago

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Apr 29, 2025, 11:30 AM EDT - 4 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

ACLX BSX DHR GKOS ISRG LLY RDNT

Insmed To Present at the BofA Securities 2025 Health Care Conference

Apr 29, 2025, 7:00 AM EDT - 4 months ago

Insmed To Present at the BofA Securities 2025 Health Care Conference

Insmed: Poised For Transformation Beyond ARIKAYCE

Apr 25, 2025, 11:58 AM EDT - 5 months ago

Insmed: Poised For Transformation Beyond ARIKAYCE

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Apr 24, 2025, 7:00 AM EDT - 5 months ago

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Apr 23, 2025, 5:00 PM EDT - 5 months ago

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

Apr 23, 2025, 7:00 AM EDT - 5 months ago

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 6 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN DNLI GPCR MRK SWTX

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

Mar 25, 2025, 8:00 AM EDT - 6 months ago

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says

Feb 25, 2025, 4:19 PM EST - 7 months ago

Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Feb 24, 2025, 8:00 AM EST - 7 months ago

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 12:50 PM EST - 7 months ago

Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Feb 20, 2025, 7:00 AM EST - 7 months ago

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

Insmed To Present at March 2025 Investor Conferences

Feb 11, 2025, 8:00 AM EST - 7 months ago

Insmed To Present at March 2025 Investor Conferences

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Feb 10, 2025, 8:00 AM EST - 7 months ago

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity

Feb 7, 2025, 10:30 AM EST - 7 months ago

Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

Feb 6, 2025, 8:00 AM EST - 7 months ago

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Jan 10, 2025, 8:00 AM EST - 8 months ago

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 8:00 AM EST - 9 months ago

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Insmed To Present at December 2024 Investor Conferences

Dec 2, 2024, 8:00 AM EST - 10 months ago

Insmed To Present at December 2024 Investor Conferences

Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data

Nov 20, 2024, 2:09 PM EST - 10 months ago

Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data

Insmed To Present at November 2024 Investor Conferences

Nov 6, 2024, 8:00 AM EST - 11 months ago

Insmed To Present at November 2024 Investor Conferences

bemore
bemore Sep. 13 at 2:10 PM
$INSM In its second-quarter 2025 investor letter, TimesSquare Capital Small Cap Growth Strategy highlighted stocks such as Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company that develops therapeutic products for patients with serious and rare diseases. The one-month return of Insmed Incorporated (NASDAQ:INSM) was 14.12%, and its shares gained 97.25% of their value over the last 52 weeks. "Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that deserve premium pricing, or specialized service providers. Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company engaged in developing therapies for patients with rare diseases, jumped 31%. During the quarter, the company reported impressive safety and efficacy data from its Phase 2 trial of Treprostinil Palmitil inhalation powder for treating arterial hypertension."
0 · Reply
kelrock90
kelrock90 Sep. 11 at 4:59 PM
$INSM premarket for 9-11-25 was $175.62
2 · Reply
pianoman439
pianoman439 Sep. 11 at 1:00 PM
$INSM how can you not love the action of Insmed stock? How can you not grieve the tragedy and recent tragedies in my nation? 😢
0 · Reply
Hello_AI
Hello_AI Sep. 11 at 6:21 AM
$INSM bullish
0 · Reply
pianoman439
pianoman439 Sep. 10 at 3:17 PM
$INSM
0 · Reply
pianoman439
pianoman439 Sep. 10 at 12:10 PM
$INSM JP Morgan Buy 153
0 · Reply
TalkMarkets
TalkMarkets Sep. 10 at 9:34 AM
Potential Pause In Gold Futures Rally? Here's What Wyckoff Effort Vs. Results Reveals $RDDT $INSM $WWW $GLD $SLV https://talkmarkets.com/content/commodities/potential-pause-in-gold-futures-rally-heres-what-wyckoff-effort-vs-results-reveals?post=521612&userid=166882
0 · Reply
pianoman439
pianoman439 Sep. 10 at 1:19 AM
$INSM what an awesome presentation! What a miraculous story! And that’s only the half of it. ALS and DMD research is bringing Insmed full circle from the days Genentech tried to destroy the tiny fledgling Insmed over a paradigm changing short stature compound.
1 · Reply
JoeB07
JoeB07 Sep. 9 at 9:21 PM
$INSM CEO describes company as a "freight train". Going to be an epic year.
0 · Reply
AlbertSan
AlbertSan Sep. 9 at 9:20 PM
$INSM
0 · Reply
JoeB07
JoeB07 Sep. 9 at 9:20 PM
$INSM There are 30 million CRSsNP patients. The phase III trial is targeting the most severe. CRSsNP is considered the bronchiectasis of the nasal pathway.
0 · Reply
JoeB07
JoeB07 Sep. 9 at 9:17 PM
$INSM CEO states TPIP is AS exciting as DPP1. Massive market opportunity.
0 · Reply
JoeB07
JoeB07 Sep. 9 at 9:15 PM
$INSM CEO just doubled down on CRSsNP being a bigger market than bronchiectasis. Called it a "significant readout" for the company coming by year end.
0 · Reply
LargeCoffee69
LargeCoffee69 Sep. 9 at 7:41 PM
$INSM Cant be stopped
0 · Reply
Gwaadin
Gwaadin Sep. 9 at 7:14 PM
$INSM she’s a beast. Nuff said.
0 · Reply
pianoman439
pianoman439 Sep. 9 at 6:14 PM
$INSM The shorts worst nightmare is coming to pass. They increased their position by 1 million shares before the UTHR data release, I suppose thinking that good news on that front would hurt Insmed. Reality slapped them across the face, and keeps on slapping them hard day after day. With well over $1.5 billion on the line, and deep underwater, what will their next move be?
1 · Reply
webelieveinhistory
webelieveinhistory Sep. 9 at 4:40 PM
$INSM On its way to $150
1 · Reply
bemore
bemore Sep. 8 at 3:42 PM
$INSM Guggenheim raises pt to 172 from 125
0 · Reply
30DeltaSpy
30DeltaSpy Sep. 8 at 2:43 PM
$INSM wow smart money moves
0 · Reply
bemore
bemore Sep. 8 at 1:43 PM
$INSM Morgan Stanley conference tomorrow afternoon. Only brokerage that has a neutral on the stock. Let's see if their rating changes.
1 · Reply
Quantumup
Quantumup Sep. 8 at 12:51 PM
Guggenheim⬆️the PT on $INSM to $172 from $125, reiterated Buy-Top Pick and said, Insmed has consistently delivered on all facets of their business since we launched coverage on the company back in July 2023, and the combination of impressive data for TPIP in pulmonary hypertension (PAH), the recent Brinsupri FDA approval in non cystic fibrosis bronchiectasis (NCFB) and now the new potential expansion opportunity for TPIP into idiopathic pulmonary fibrosis (IPF) have only strengthened our already bullish views on this company. Guggenheim added:
0 · Reply
pianoman439
pianoman439 Sep. 8 at 12:27 PM
$INSM 150+ this week?
1 · Reply